Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Transthyretin Amyloid Cardiomyopathy
NCT05233163Phase 4Completed
- Sponsor
- Columbia University
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Columbia University. Started Mar 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT05233163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05233163.